- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00708097
In Situ Caries Efficacy of Fluoride Toothpastes
December 11, 2014 updated by: GlaxoSmithKline
Clinical Efficacy of Fluoride Toothpastes Using an in Situ Caries Model
This study is to evaluate the effect of fluoride dentifrices on enamel with artificial caries lesions in an in situ model
Study Overview
Detailed Description
In situ models represent an acceptable approach for testing the anti-caries potential of fluoride products.
This study is to evaluate the effect of fluoride dentifrice containing 1450 parts per million fluoride (ppm F) on enamel with artificial caries lesions in an in situ model.
The study toothpaste containing sodium fluoride (NaF) and 0.4% carbopol will be compared to 4 other dentifrices.
Comparator toothpastes include NaF toothpaste (1400 ppm F), NaF toothpaste (675 ppm F), sodium monofluorophosphate (NaMFP) and NaF toothpaste (1450 ppm F) and placebo toothpaste (0 ppm F).
Study Type
Interventional
Enrollment (Actual)
57
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University School of Dentistry
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Consent:Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Age:Aged between 18 and 80 years.
- Compliance:Understands and is willing, able and likely to comply with all study procedures and restrictions.
- General Health:Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination.
- Fluoride:Currently living in the Indianapolis, Indiana area and not taking fluoride supplements for medical reasons
- Dentures: a)Currently wearing a removable mandibular partial denture with sufficient room in both posterior buccal flange areas to accommodate two enamel specimens on each side, four specimens in total - required dimensions 12 x 7 millimeter (mm) per side. b) Willing to have their denture modified to accommodate enamel test specimens and willing and capable of wearing their removable mandibular partial dentures 24 hours per day during the experimental periods
- Dental health: Have no current active caries or periodontal disease that may compromise the study or the health of the subjects and all restorations in a good state of repair
- Salivary flow:Have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate = 0.2 milliliter (mL)/minute; gum base stimulated whole saliva flow rate = 0.8 mL/minute)
Exclusion Criteria:
- Pregnancy: Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
- Breast-feeding:Women who are breast-feeding.
- Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
- Antibiotics: Currently taking antibiotics or have taken antibiotics in the two weeks prior to the screening visit
- Clinical Study/Experimental Medication: a) Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.b) Participation in another GSKCH investigational dental product study within 7 days of first study treatment c)Previous participation in this study.
- Substance abuse: Recent history (within the last year) of alcohol or other substance abuse.
- Personnel:a) A member of the site study staff living in same household.b)An employee of the sponsor. c) Any employee of any toothpaste manufacturer or their spouse or family member
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: NaF toothpaste(1450 ppmF)
Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.
|
Fluoride
Other Names:
|
|
Active Comparator: NaF toothpaste (1400 ppmF)
Study toothpaste containing 1400 ppm F as NaF
|
Fluoride
Other Names:
|
|
Active Comparator: NaMFP/NaF toothpaste (1450 ppmF)
Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF
|
Fluoride
Other Names:
Fluoride
|
|
Active Comparator: NaF toothpaste (675 ppmF)
Study toothpaste containing 675 ppm F as NaF
|
Fluoride
Other Names:
|
|
Placebo Comparator: Placebo toothpaste (0 ppmF)
Fluoride free placebo toothpaste (0 ppm F)
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)
Time Frame: Baseline to 14 days
|
SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester.
SMH was determined by measuring the length of the indentations of enamel specimens.
An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface.
Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula [(D-R)/(D-B)]*100.
|
Baseline to 14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage SMHR of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (675ppmF) and Placebo Toothpaste (0ppmF)
Time Frame: Baseline to 14 days
|
SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester.
SMH was determined by measuring the length of the indentations of enamel specimens.
An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface.
Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula [(D-R)/(D-B)]*100.
|
Baseline to 14 days
|
|
Percentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF)
Time Frame: Baseline to 14 days
|
SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester.
SMH was determined by measuring the length of the indentations of enamel specimens.
An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface.
Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula [(D-R)/(D-B)]*100.
|
Baseline to 14 days
|
|
Enamel Fluoride Uptake (Sound Enamel Specimens)
Time Frame: Baseline to 14 days
|
Enamel fluoride uptake was determined using the microdrill enamel biopsy technique.
The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores.
The difference between treatments was calculated with respect to fluoride uptake by enamel.
|
Baseline to 14 days
|
|
Enamel Fluoride Uptake (Demineralized Specimens)
Time Frame: Baseline to 14 days
|
Enamel fluoride uptake was determined using the microdrill enamel biopsy technique.
The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores.
The difference between treatments was calculated with respect to fluoride uptake by enamel.
|
Baseline to 14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
July 1, 2008
Study Registration Dates
First Submitted
July 1, 2008
First Submitted That Met QC Criteria
July 1, 2008
First Posted (Estimate)
July 2, 2008
Study Record Updates
Last Update Posted (Estimate)
January 1, 2015
Last Update Submitted That Met QC Criteria
December 11, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- T3508565
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Caries
-
3Shape A/SNew York UniversityNot yet recruitingCaries,Dental | Caries; Initial | Caries Assessment | Caries Active | Caries Root
-
Albert MehlNot yet recruitingCaries; Initial | Caries Assessment | Caries; DentinSwitzerland
-
Ain Shams UniversityCompletedPulpitis | Caries | Caries,Dental | Reversible Pulpitis | Caries Class I | Caries; DentinEgypt
-
Hacettepe UniversityRecruitingDeep Caries | Dentin CariesTurkey
-
Mansoura UniversityActive, not recruitingOcclusal Caries | Proximal CariesEgypt
-
Mansoura UniversityActive, not recruitingProximal Caries | Occlual CariesEgypt
-
University of MinnesotaCompletedUsing Motivational Interviewing To Reduce Parental Risk-Related Behaviors For Early Childhood CariesCaries | Caries,DentalUnited States
-
Cairo UniversityAin Shams UniversityCompletedTooth Caries | Proximal CariesEgypt
-
Cairo UniversityNot yet recruitingPit and Fissure Caries | Caries; InitialEgypt
-
The Children's Hospital of Zhejiang University...Not yet recruitingCaries | Severe Early Childhood Caries
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States